Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S. Food and Drug Administration (“FDA”) has recently agreed a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study of tifcemalimab (product code: TAB004/JS004), an anti-BTLA monoclonal antibody used in combination with toripalimab, an anti-PD-1 monoclonal antibody, as consolidation therapy for patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy may proceed. Junshi Biosciences will officially initiate the phase 3 clinical study in the near future.

According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China. Lung cancer can be broadly categorized into non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”), based on cell type. Specifically, small cell lung cancer is the most invasive subtype of lung cancer, accounting for about 15%-20% of all lung cancer cases with characteristics such as rapid progression, early metastasis, and poor prognosis. Small cell lung cancer includes limited-stage small cell lung cancer (“LS-SCLC”) and extensive-stage small cell lung cancer, and LS-SCLC accounts for about one-third of all small cell lung cancer cases. For LS-SCLC patients who are unable to undergo surgery or refuse it, chemo-radiotherapy (CRT) is the standard of care (SOC). However, even after standard cardiac resynchronization therapy, the prognosis remains poor, with a median progression-free survival (mPFS) of approximately 13.5 months, a median overall survival (mOS) of 16-24 months, and a 5-year survival rate of only 15%-26%. There is still a huge unmet medical need for the treatment of LS-SCLC, and there is an urgent need to explore more effective and well-tolerated therapeutic approaches in clinical practice. There are currently no globally approved immune checkpoint inhibitors specifically for LS-SCLC.

The study to be initiated by Junshi Biosciences is a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study aimed to evaluate the efficacy and safety of tifcemalimab in combination with toripalimab, toripalimab alone, or placebo as consolidation therapy for LS-SCLC patients without disease progression following CRT. This study serves as the first confirmatory trial of BTLA-targeted drugs, and the principal investigator will be academician Jinming YU, President of Shandong Cancer Hospital & Institute. The study plans to enroll 756 patients from China, the United States, Europe, and other regions across the world.

“In recent years, immune-oncology (I-O) therapy has made rapid advancements, particularly in the field of lung cancer, where it has emerged as the standard of care for first-line treatment of advanced NSCLC,” said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. “Regarding more aggressive SCLC, however, the progress in I-O therapy has been relatively slow. To date, no immune checkpoint inhibitor has received approval for the treatment of LS-SCLC. Tifcemalimab is Junshi Biosciences’ first independently developed ‘first-in-class’ product, and it bears the potential to be combined with our cornerstone antibody, toripalimab, and enhance patient response to I-O therapy, increase the number of patients who can benefit from I-O therapy, and introduce new breakthroughs in the treatment of LS-SCLC patients!”

About Tifcemalimab (JS004/TAB004)

Independently developed by Junshi Biosciences, tifcemalimab is the world’s first-in-human recombinant humanized anti-BTLA (B- and T-lymphocyte attenuator) monoclonal antibody against cancer. Tifcemalimab has been agreed to enter phase 3 clinical study, and several phase 1b/2 clinical trials of tifcemalimab in combination with toripalimab in patients with different types of tumors are currently underway in China and the United States.

The B and T lymphocyte attenuator (BTLA), the target of tifcemalimab, was discovered in 2003. BTLA is a member of the CD28 receptor family and possesses a single IgSF V extracellular domain. Its sequence is similar to other molecules within the CD28 family (such as PD-1 and CTLA-4).

BTLA is expressed in the T lymphocyte, B lymphocyte, and dendritic cell subpopulations. In 2005, the interaction between BTLA and its ligand, Herpes virus entry mediator (HVEM), was discovered. HVEM, a TNF receptor, is extensively expressed in the hematopoietic system and has been confirmed as the ligand of BTLA.

BTLA is an immunoglobulin-associated membrane protein; its protein structure is similar to that of the transmembrane receptors (CTLA-4 and PD-1). Under normal physiological conditions, after BTLA binds with its ligand HVEM, it inhibits the over-activation of lymphocytes in the human body, thus preventing autoimmune injuries.

By binding with BTLA, tifcemalimab blocks the HVEM-BTLA interaction, thereby obstructing the BTLA-mediated inhibitory signal pathways and activating the tumor-specific lymphocytes.

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.

In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (“FDA”). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8866702

Legacy, Storytelling and Community: How INVNT.ATOM™, [INVNT GROUP]’s digital innovation agency, transformed Automobili Lamborghini’s global brand footprint with its Web3 initiatives

INVNT.ATOM collaborated with the legendary automotive brand to launch two successful Web3 campaigns across 12 months, invigorating the iconic brand’s leadership in innovation, art and design.

Singapore, June 28, 2023 (GLOBE NEWSWIRE) — Across 2022 and 2023, INVNT.ATOM™, [INVNT GROUP]™’s digital and Web3 Innovation division delivered two historic NFT campaigns in collaboration with Automobili Lamborghini, as the legacy super sportscar leader celebrated their 60th anniversary and entered its hybrid era.

With global features in media outlets such as Forbes, Fast Company, Be in Crypto, and an announcement from Lamborghini’s CEO Steve Winkelmann that Lamborghini’s sports cars are sold out until 2024, [INVNT GROUP] has concluded two back to back campaigns in partnership with Automobili Lamborghini.

‘Lamborghini Ultimate’ a world first 1:1 NFT & The Last Aventador Coupé in collaboration with contemporary artist Krista Kim and Grammy award winning artist Steve Aoki, and most recently “The Epic Road Trip”, an 8-month Web3 initiative with utilities which cultivated a community of global Web3 loyalists around the world. The conclusion of “The Epic Road Trip” marked the brand’s 60th anniversary where the Italian marque revealed the “Revuelto”, the brand’s first dual-powertrain supercar – continuing their commitment to a more sustainable future.

Lamborghini was the first super sports car  brand to enter the world of digital collectibles, with their release of digital bitstamps in 2020. In partnership with [INVNT GROUP], two major Web3 initiatives have followed suit, cultivating a new community of a younger tech audience, and established loyalists to mark the hybrid era, as the brand races towards complete electrification by 2030.

[INVNT GROUP] partnered with Steve Aoki and Krista Kim to create an audiovisual collaboration which saw the creation of the world’s first 1:1 NFT supercar, auctioning off the physical version of the last ever Aventador Coupe with auction house RM Sotheby’s. The NFT paired with the physical sports car sold at an auction price of $1.6M, placing the purchase price in the top 10 new Lamborghinis ever sold.

On the back of the global success and impact of“Lamborghini Ultimate” Lamborghini continued their partnership with [INVNT GROUP] with the launch of “The Epic Road Trip”. This 8-month long campaign showcased monthly prizes and NFT reveals, concluding in a global celebration of the brand’s 60th anniversary and the ultimate reveal of the Revuelto. The consequential results of “The Epic Road Trip ” showcased a nod to the brand’s transformation, with 10.5x campaign ROI. Collectively, both campaigns have garnered 1.8 billion global editorial media impressions, across 2.4K featured editorial placements, totalling over $17.3M USD of advertising value.

“These results demonstrate how incredibly powerful leveraging Web3 is in any modern marketing strategy,” says Scott Cullather,  President & CEO of [INVNT GROUP], and CEO of INVNT.ATOM, “These are highly engaged, hands-on collectors with a passion for the Lamborghini brand. By focusing on a curated group of brand loyalists, Lamborghini was able to both deepen its connection with its biggest fans while also welcoming new people to be a part of its timeless heritage and future. As an ultra-luxury brand that sold just 9,233 vehicles in 2022, every boost in purchase intent is worth millions.”

“Lamborghini is an aspirational brand, and Web3 is a bridge to people that are dreaming Lamborghini, but also for people that are not familiar with the brand and more familiar with art, design and NFTs. It’s an example of how art and design are connected to our brand. And the good thing is that with the NFTs we’re able to make sure that this dream is also in the reach for the fan,” said Christian Maestro, Marketing Director of Automobili Lamborghini, in Carly Reilly’s Overpriced JPEGS Podcast Series with Scott Cullather.

As the brand continues its journey towards complete hybridization of its lineup by 2025, expect further experimentation at the leading edge of community, blockchain and utility.

Driven by [INVNT GROUP]’s “Challenge Everything” mantra backed by world-class storytelling, both campaigns immersed the legacy brand into the world of Web3, whilst also adopting elements of the physical world into the journey. The phygital experiences, told a tale of brand transformation, as Lamborghini fans are given brand new avenues to engage with the legacy brand into the future.

About INVNT.ATOM™ INVNT.ATOM, part of [INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT™, is an innovation and brand experience agency devoted to helping global brands chart a course, navigate, activate, and create new opportunities at the digital frontier of Web3. Headquartered in Singapore, the collective of strategists, marketers, creators, programmers, matchmakers, and thought leaders, turn strategies into stories and stories into experiences that engage communities on the global stage. For more information about INVNT.ATOM, visit: www.invntatom.com.

About [INVNT GROUP]™ [INVNT GROUP] was established as an evolution of the founding global live brand storytelling agency INVNT. Led by President and CEO, Scott Cullather, [INVNT GROUP], THE GLOBAL BRANDSTORY PROJECT™ represents a portfolio of disciplines designed to help forward-thinking organizations innovate and impact audiences everywhere. The GROUP consists of modern brand strategy firm, Folk Hero; creative-led culture consultancy, Meaning; production studio & creative agency, HEVĒ; events for colleges and universities, INVNT Higher Ed; digital innovation division, INVNT.ATOM; creative multimedia experience studio, Hypnogram; and the original live brand storytelling agency, INVNT. For more information visit www.invntgroup.com.

Media Kit (High-res imagery and videos)


Paola Cracknell
+61 452 452 051  

Jhonathan Mendez De Leon
+1 347 819 2089

GlobeNewswire Distribution ID 8866009

LeddarTech ปล่อยตัวอย่างการผลิตของ LeddarVision Front-Entry (LVF-E) ซอฟต์แวร์ฟิวชันและการรับรู้ระดับต่ำที่ครอบคลุมซึ่งมีโปรเซสเซอร์ TI TDA4VM-Q1 สำหรับแอปพลิเคชัน ADAS L2/L2+

ตัวอย่าง “B” ของ LVF-E ของ LeddarTech ที่มี ECU ในตัว ได้นำเสนอโซลูชันที่ไม่เคยมีมาก่อนในภาคอุตสาหกรรมที่นำประสิทธิภาพและความน่าเชื่อถือระดับสูงของฟิวชันระดับต่ำมาสู่ตลาด ADAS ระดับเริ่มต้น

ควิเบก, June 29, 2023 (GLOBE NEWSWIRE) — LeddarTech®บริษัทซอฟต์แวร์ยานยนต์ที่ให้บริการเทคโนโลยีซอฟต์แวร์ฟิวชันเซนเซอร์และการรับรู้ระดับต่ำที่ได้รับการจดสิทธิบัตรแล้วสำหรับ ADAS และ AD มีความยินดีที่จะประกาศว่าตัวอย่าง “B” ของระบบช่วยเหลือบนทางหลวง ADAS L2/L2+ ระดับเริ่มต้นและสแต็กซอฟต์แวร์ฟิวชันและการรับรู้ระดับต่ำ NCAP 2025/GSR 2022 ระดับ 5 ดาวของ LeddarVision™ ซึ่งปรับให้เหมาะสมสำหรับโปรเซสเซอร์ TDA4VM-Q1 (8 TOPS) จาก Texas Instruments มีวางจำหน่ายแล้ว

ผลิตภัณฑ์ LeddarVision Front-Entry (LVF-E) ที่เปิดตัวอย่างเป็นทางการในปลายปี 2565 ได้รับการออกแบบมาสำหรับลูกค้าที่ต้องการพัฒนาแอปพลิเคชันความปลอดภัย ADAS ระดับเริ่มต้นและความช่วยเหลือบนทางหลวง L2/L2+ การนำเสนอตัวอย่าง “B” ได้นำความก้าวหน้าที่น่าตื่นเต้นมาสู่ LVF-E ที่ขับเคลื่อนโดยโปรเซสเซอร์ Texas Instruments (TI) TDA4VM-Q1 ด้วยการใช้ประโยชน์จากตัวอย่าง “B” เหล่านี้ ทำให้ LVF-E มอบประโยชน์ด้านต้นทุนและประสิทธิภาพอย่างมากสำหรับฟิวชันระดับต่ำ ซึ่งเป็นการปูทางไปสู่การเร่งการนำระบบ L2/L2+ ไปปรับใช้ นอกจากนี้ ความก้าวหน้านี้ช่วยลดข้อกำหนดของเซ็นเซอร์และโปรเซสเซอร์ได้อย่างมีประสิทธิภาพ ทำให้สามารถเข้าถึงตัวผลิตภัณฑ์ได้มากขึ้น อีกทั้งมีประสิทธิภาพสำหรับการใช้งานอย่างกว้างขวางอีกด้วย โซลูชัน LeddarVision Front-Entry ยังถือเป็นการออกแบบแรกที่ตระกูลโปรเซสเซอร์ TDA4x ที่มีการบูรณาการสูงของ TI และประหยัดต้นทุนนั้นได้รับการนำเสนอในโซลูชันฟิวชันระดับต่ำ


  • ประสิทธิภาพที่สูงขึ้น:
    • เพิ่มช่วงที่มีประสิทธิภาพของเซ็นเซอร์เป็นสองเท่า จึงช่วยให้ ADAS ประสิทธิภาพสูงกำหนดเป้าหมายมาตรฐาน NCAP 2025 และ GSR 2022 ระดับ 5 ดาวได้ด้วยต้นทุนเซ็นเซอร์และระบบที่ต่ำกว่า
  • ลดต้นทุน:
    • ลดข้อกำหนดด้านฮาร์ดแวร์ลง: เป็นครั้งแรกในอุตสาหกรรมที่มีการเปิดใช้งานด้วยกล้องด้านหน้า 120 องศาที่มีความละเอียด 1 ถึง 2 ล้านพิกเซลจำนวนหนึ่งตัว และเรดาร์มุมด้านหน้าระยะสั้นสองตัวในการกำหนดค่า 1V2R
    • การใช้งานอย่างมีประสิทธิภาพบนแพลตฟอร์ม TDA4VM-Q1 ช่วยให้บรรลุการเป็นหนึ่งในการใช้ต้นทุนระบบที่ต่ำที่สุดสำหรับ ADAS ระดับเริ่มต้น L2/L2+ โดยไม่สูญเสียประสิทธิภาพของระบบ

เยี่ยมชม หน้าผลิตภัณฑ์ LVF-Eของ LeddarTech สำหรับข้อมูลเพิ่มเติมและขอตัวอย่าง

“OEM และ Tier 1 มุ่งมั่นที่จะเพิ่มความสามารถด้านราคาที่เหมาะสมของ ADAS LeddarTech บรรลุเป้าหมายนี้โดยการลดจำนวนเซ็นเซอร์และค่าใช้จ่าย ทำให้ระบบมีความยุ่งยากน้อยลงและลดต้นทุนโปรเซสเซอร์ ในขณะที่ส่งมอบฟิวชันระดับต่ำ (LLF) และการรับรู้ระดับต่ำที่มีประสิทธิภาพสูงใน ECU เกรดยานยนต์ได้ การแสดงให้เห็นถึงความเข้ากันได้ของฟิวชันระดับต่ำกับโปรเซสเซอร์ TDA4VM-Q1 ของ TI ถือเป็นแถลงการณ์ทางการตลาดที่ทรงพลัง ความพร้อมใช้งานของตัวอย่าง ‘B’ ของชุดซอฟต์แวร์ LVF-E ของเราจะนำเสนอโซลูชันการรับรู้ที่คุ้มค่าโดยใช้ LLF ซึ่งเป็นก้าวสำคัญสำหรับเทคโนโลยีของ LeddarTech ในตระกูลโปรเซสเซอร์ TDA4x ยอดนิยม” Charles Boulanger ประธานเจ้าหน้าที่บริหารของ LeddarTech กล่าว

เกี่ยวกับ LeddarTech

LeddarTech เป็นบริษัทซอฟต์แวร์ระดับโลกที่ก่อตั้งขึ้นในปี 2550 ซึ่งมีสำนักงานใหญ่อยู่ที่คิวเบคซิตี้และมีศูนย์การวิจัยและพัฒนาอยู่ที่มอนทริออล โตรอนโต และเทลอาวีฟโดยได้พัฒนาและจัดหาโซลูชันซอฟต์แวร์การรับรู้ที่ครอบคลุมซึ่งช่วยเปิดใช้งานการปรับใช้ ADAS และแอปพลิเคชันการขับขี่อัตโนมัติ เทคโนโลยีซอฟต์แวร์เกรดยานยนต์ของ LeddarTech ใช้อัลกอริทึมการมองเห็นของคอมพิวเตอร์และ AI เพื่อสร้างแบบจำลองสภาพแวดล้อม 3 มิติที่มีความแม่นยำสูง ซึ่งจะช่วยให้ตัดสินใจได้ดีขึ้น อีกทั้งยังช่วยให้การนำทางปลอดภัยยิ่งขึ้นอีกด้วย เทคโนโลยีประสิทธิภาพสูง ปรับขนาดได้ และคุ้มค่านี้ใช้ประโยชน์จาก OEM และซัพพลายเออร์ระดับ 1-2 เพื่อการใช้งานโซลูชันยานยนต์และรถออฟโรดได้อย่างมีประสิทธิภาพ

LeddarTech เป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ ๆ ในด้านยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัย ด้วยเทคโนโลยีทั้งที่จดสิทธิบัตรแล้วหรือที่รอการอนุมัติมากกว่า 150 รายการที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ การรับรู้ของยานพาหนะที่ดีขึ้นมีความสำคัญอย่างยิ่งในการทำให้ยานยนต์ทั่วโลกปลอดภัยขึ้น มีประสิทธิภาพมากขึ้น ยั่งยืน และราคาไม่แพง นี่จึงเป็นสิ่งที่ผลักดันให้ LeddarTech กลายเป็นโซลูชันซอฟต์แวร์ฟิวชันเซ็นเซอร์และการรับรู้ที่ได้รับการยอมรับอย่างกว้างขวางที่สุด

ดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และที่ LinkedIn, Twitter, Facebook และ YouTube

ติดต่อ:Daniel Aitken รองประธานฝ่ายการตลาดระดับโลก การสื่อสาร และนักลงทุนสัมพันธ์ของ LeddarTech Inc. โทร.: + 1-418-653-9000 ต่อ 232 daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายอื่น ๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนที่ใช้เพื่อระบุผลิตภัณฑ์หรือบริการของเจ้าของที่เกี่ยวข้อง

GlobeNewswire Distribution ID 8866420

White pepper in Babel losing ground to tin and palm oil

Pangkalpinang (ANTARA) – Bangka Belitung (Babel) is renowned not only for its natural beauty and tin commodity but also for its high-quality white pepper.The pepper produced in this province has gained global recognition due to its unique characteristics not found in other regions. White pepper has emerged as one of the primary commodities of the islands and has been a popular agricultural product among the local community for generations. It has received the geographical indication (GI) certification from the Ministry of Law and Human Rights, with registry number 000000004, dated January 21, 2010. Babel white pepper stands out in terms of quality and distinctive taste compared to pepper from other regions. Its appeal lies in its high piperine content, with a sharpness level ranging from 5-7 percent, and a strong essential oil aroma. White pepper is often used to add a spicy flavor, impart aromatic properties to dishes, and eliminate fishy smells. Bangka Belitung is the largest producer of white pepper in Indonesia, followed by Lampung, West Kalimantan, East Kalimantan, Papua, West Nusa Tenggara, North Maluku, and Yogyakarta. Despite being the top producer and having high quality, the availability of pepper in Babel is declining each year in terms of both land area and production. Data from the province’s agriculture service between 2018-2022 indicates that pepper production increased only in 2019, while the land area and production of pepper commodities decreased during the 2020-2022 period. The area of pepper plantations reached 51,404 hectares in 2018 and increased to 52,688 hectares in 2019. However, it declined to 52,192 hectares in 2020, 49,465 hectares in 2021, and further dropped to 44,548 hectares in 2022. The production of pepper is directly proportional to the plantation land area. Approximately 32,810 tons of pepper were harvested in 2018, which increased to 33,458 tons in 2019. However, production declined to 29,441 tons in 2020, and the downward trend continued with only 27,167 tons recorded in 2021, reaching 26,408.82 tons in 2022. The decline in pepper plantation area and production can be attributed to various factors, including the COVID-19 pandemic and the price of pepper in the global market. Pepper farmers have been shifting their professions to become tin miners or work in palm oil plantations due to the low price of white pepper. To incentivize farmers to continue cultivating pepper, there is a need for collaborative efforts to improve the pepper trading system and increase the price of white pepper in local, national, and international markets. The Pepper Management, Development, and Marketing Agency (BP3L) of Bangka Belitung Islands, in coordination with the local government, the Ministry of Trade, and the International Pepper Community (IPC), aims to establish a pepper trading system that can encourage farmers to focus on pepper cultivation. Implementing a pepper trading system would enable Bangka Belitung to become a determinant of pepper prices in Indonesia, similar to countries like Malaysia, India, and Brazil, which already have such systems in place. Suganda Pandapotan Pasaribu, the Acting Governor of Bangka Belitung, urges pepper business actors to engage in immediate discussions regarding the pepper trading system, setting aside personal interests and prioritizing the collective benefits. The Central Bangka District Government in Babel also encourages farmers to persevere in planting pepper despite the unstable price. The Head of the Central Bangka Agricultural Service, Sajidin, acknowledges that some farmers have shifted to working in the palm oil and tin ore mining sectors, but emphasizes the long-term benefits of pepper cultivation. Pepper plants can thrive for many years under the right conditions, contributing to the strengthening of the local economy. The local government continues to support farmers by distributing superior seeds and providing technological equipment to boost production, thereby reducing production costs through the utilization of the latest technology and organic fertilizers. Through these concerted efforts, it is hoped that pepper, the “King of Spice”, will regain its position as the main commodity from Babel. This would prevent a further shift towards tin and palm oil commodities that have started to replace current pepper plantations. Pepper farmers who are currently persevering are reminded not to be enticed by the instant profits offered in the mining sector. The mining sector provides only temporary benefits, as the cultivated land becomes unusable, resulting in a loss of livelihood for the community. Therefore, support from the local government and other relevant parties is crucial to maintaining the price of pepper and establishing a sustainable trading system that serves as an economic source for the people of Bangka Belitung.

Source: Antara News Agency

Value of sacrificial animals, alms show economic recovery: Governor

Bandung, West Java (ANTARA) – West Java Governor Ridwan Kamil stated that the community’s sacrificial animals and zakat (alms) that increased in value during this Eid al-Adha showed the province’s post-pandemic economic recovery.Kamil conveyed this statement after performing the Eid al-Adha prayer along with thousands of residents at the Al Jabbar Grand Mosque, Bandung City, West Java, on Thursday. During this year’s Eid al-Adha, he noted that the value of sacrificial animals increased to Rp152 billion (US$10.1 million) as compared to the previous year. Meanwhile, he noted that Rp3.4 trillion (US$226.7 million) of alms money was already being managed. “In 2022, the alms recorded was Rp2.4 trillion (US$160 million). This year, from January to June, it has reached Rp3.4 trillion,” Kamil explained. His side has forecast that the collection of alms and other funds will reach Rp3.7 trillion by the end of December. On that occasion, Kamil also bid farewell to his post of West Java governor, as his term of office was coming to an end. He expressed optimism that the acting governor, who will assume the position, would continue to make improvements in the economic sector. In addition, he ensured the proper placement of street traders around the Al Jabbar Grand Mosque. Kamil said his side has evaluated the location of street vendors at the mosque and had made improvements to it, as earlier, they were scattered in the first three months since the mosque’s inauguration. “This morning, I am grateful for the extraordinary numbers, like the connectivity index, religious harmony index, and other indexes,” he stated. Bank Indonesia (BI) West Java has forecast a three-percent annual inflation rate in the province this year. Head of the BI West Java Representative Office Erwin Gunawan estimated that this year’s annual inflation will be stable. West Java recorded economic growth of five percent in the first quarter of 2023. Related news: Productivity key for sustained Asia recovery: Minister

Source: Antara News Agency

Family Day emphasizes families’ stunting-reduction role: BKKBN

Jakarta (ANTARA) – The 30th National Family Day in 2023 offers the right momentum to emphasize the role of families in reducing the stunting prevalence rate, the National Population and Family Planning Board (BKKBN) stated.”In the efforts to pursue stunting rate reduction, the family has a very crucial role, particularly in (adopting) good care practices and creating an environment with sanitation that meets health standards,” head of BKKBN Hasto Wardoyo remarked here on Thursday. Stunting is a condition in which children’s growth and development are compromised due to chronic nutritional deficiency, repeated infections, and an environment that is not supportive, he explained. The condition is marked by short height in children that does not meet the standard of height in those their age, he remarked. Wardoyo cited the 2022 National Nutrition Status Study (SSGI) that showed the stunting prevalence rate was at 21.6 percent, thereby indicating that one in every five children has stunted growth. “Hence, broadening the horizon and knowledge of families and communities are important in preventing stunting and preparing children, so they would grow and develop optimally and become an advanced generation,” he emphasized. Wardoyo underscored the need to increase everyone’s commitment in pushing for the role of families in stunting reduction, so as to ensure that the program ran successfully. During the fight for freedom and independence in 1945, many were asked to join the war, deputy of advocacy, initiative, and information at BKKBN Sukaryo Teguh Santoso stated. Several families had to sacrifice their lives, assets, and family members in order to gain independence, he noted. Despite independence being proclaimed on August 17, 1945, the Dutch only gave such acknowledgement on June 22, 1949, he remarked. t that time, the fighters, who lost their lives to the war, were buried, with some being known while others going unrecognized, he pointed out. On the other hand, fighters, who made it alive, reunited with their families after being separated for long, he added. The day when fighters got to finally see their families on June 29, 1949, became the start of National Family Day, as per Presidential Decree Number 39 of 2014 on National Family Day that set the date for the national day, Santoso stated. On June 29, 1970, the government officially made family planning a national program, coinciding with the establishment of BKKBN, which was named the National Coordination and Family Planning Board, he remarked. “The fight to build Indonesia and families is done (simultaneously). Building families also means building the nation. The commemoration of Family Day is the initiative to remind all Indonesians of how important family is,” Santoso concluded.

Source: Antara News Agency

Minister-PSSI coordinate to evaluate JIS readiness for U-17 World Cup

Jakarta (ANTARA) – Public Works and Public Housing Minister Basuki Hadimuljono expressed readiness to coordinate with National Football Association Head Erick Thohir to prepare and evaluate facilities at the Jakarta International Stadium (JIS) for the U-17 World Cup.”I will coordinate with him (Head of PSSI) immediately. If it needs to be renovated, (then it will be) renovated,” he stated at the ministry’s office here on Thursday. Hadimuljono affirmed that he would check the stadium after establishing coordination with Thohir. ccording to the minister, the most crucial aspects of that stadium that should be addressed are the access and parking space. The Dewaband concert held earlier at JIS had shown that concertgoers faced difficulty in exiting the place, the minister pointed out. “Later, we will evaluate. I want to coordinate with Head of PSSI Erick Thohir,” he noted. Minister Hadimuljono revealed that the stadiums prepared for the U-20 World Cup can be used to host the U-17 World Cup. He explained that as many as 26 stadiums were prepared for the U-20 World Cup, with six main ones located in Palembang, Jakarta, Solo, Bandung, Bali, and Surabaya. He affirmed that those stadiums are still fit to be used as an arena, given their infrastructure, such as lighting and grass, have met FIFA’s standards. Should there be anything that needs to be tweaked, it would not be something major, he stated. “Mr Head of PSSI said that FIFA will come again to check. I have no idea yet when FIFA will come to check. I will contact and coordinate with the head of PSSI first. Hopefully, now, I can come along to do the check,” Minister Hadimuljono elaborated. In April 2023, FIFA ended up revoking Peru’s appointment as host of the U-17 World cup due to lacking infrastructure, although they have been appointed as the host since four years. FIFA then appointed Indonesia to host the 2023 U-17 World Cup. The decision came after the FIFA council meeting at their headquarters in Zurich, Switzerland. The global tournament is scheduled from November 10 to December 2, 2023. Related news: Sports ministry welcomes RI’s appointment as U-17 World Cup host

Source: Antara News Agency

BKKBN holds mass circumcision, blood donation drive to mark Harganas

This collaboration shows that in achieving common (national) goals, BKKBN cannot work alone. Jakarta (ANTARA) – The National Population and Family Planning Agency (BKKBN) organized a mass circumcision and blood donation drive in collaboration with the military ahead of the 30th National Family Day (Harganas), which is observed every June 29.”This collaboration shows that in achieving common (national) goals, BKKBN cannot work alone. Support from all parties is important for the success of BKKBN programs,” Chief Inspector of BKKBN Ari Dwikora Tono said here on Wednesday. Eight-two children took part in the mass circumcision and 102 people donated their blood at the Central Jakarta Regional BKKBN Office on Tuesday (June 27, 2023), he informed. Donating blood is beneficial not only for recipients, but also for donors, he said. The activity can reduce blood viscosity, the level of iron in the body, as well as the risk of cholesterol and heart disease. Meanwhile, the implementation of mass circumcision was one of the agency’s attempts to improve the sexual and reproductive health of the community, thus strengthening the resilience of Indonesian families. In addition to being an obligation under Islamic law, circumcision has many medical benefits. According to the website of Mayo Clinic, an American academic medical center, circumcision can lower the risk of urinary tract infections, sexually transmitted infections, and cancer. Head of the Committee of BKKBN’sSocial Service ProgramsZamhir Setiawansaidhis party expects the activity to improve the health of Indonesian families, especially children. He also expressed the hope that the activity would help parents to circumcise their children, as a preparation for the children to face their coming of age. Earlier, BKKBN also carried out a family planning program entitled “Simultaneous Family Planning Services for One Million Acceptors” on June 14 to welcome the 30th Harganas. The event was held simultaneously in all provinces throughout Indonesia and targeted 1,244,348 acceptors.

Source: Antara News Agency